17
Jun
2023
Learning From History How to Think About the Technology of the Moment
Generative AI, the transformative technology of the moment, exploded onto the scene with the arrival in late 2022 of chatGPT, an AI-powered chatbot developed by the company OpenAI. After only five days, a million users had tried the app; after two months: 100 million, the fastest growth ever seen for a consumer application. TikTok, the previous record holder, took nine... Read More
14
Jun
2023
Immunotherapies for Cancer and More: Aaron Ring on The Long Run
Aaron Ring is today’s guest on The Long Run. Aaron is an associate professor of immunobiology at Yale University for a little while longer. He’s moving his lab to the Fred Hutchinson Cancer Center in Seattle in the summer of 2023. Early in his scientific career, Aaron has done some fascinating work in protein engineering and immunology. He has founded... Read More
13
Jun
2023
Gilead Test Drives A-Alpha Bio Platform to Find Long-Acting Biologics Against HIV
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Jun
2023
Startup Profiles: Upstream Bio Gets Another $200M, Kate Therapeutics Debuts with $51M
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Jun
2023
Alkeus, a Bootstrap Success Story, Grows Up With $150M Series B
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Jun
2023
Pharma R&D Execs Offer Extravagant Expectations for AI But Few Proof Points
As the excitement around generative AI sweeps across the globe, biopharma R&D groups (like most everyone else) are actively trying to figure out how to leverage this powerful but nascent technology effectively, and in a responsible fashion. In separate conversations, two prominent pharma R&D executives recently sat down with savvy healthtech VCs to discuss how generative AI specifically, and emerging... Read More
1
Jun
2023
Pfizer’s RSV Vaccine OK’d, Coherus Challenges Humira, & Eikon Gets a Pipeline
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
May
2023
From Structural Biology to Structuring Companies: Deb Palestrant on The Long Run
Today’s guest on The Long Run is Deb Palestrant. Deb is a partner with 5AM Ventures and the executive chair of the 4:59 Initiative. 5AM invests in early-stage startups working on a variety of novel biological targets and some of the emerging new treatment modalities – gene therapy, gene editing, oligonucleotides. As the name suggests, it’s not afraid to get... Read More
25
May
2023
ElevateBio Hauls in $401M, Blueprint Expands Label, & a String of Clinical Failures
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
May
2023
Larkspur Gets $35.5M to Make Small Molecule Cancer Immunotherapies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
May
2023
Big, If True: Opportunities and Obstacles Facing AI (Plus: Summer Reading)
Today, we’ll begin with a consideration of the promise for AI some experts see in healthcare and biopharma. Next, we’ll look at some of the obstacles – some technical, some organizational – and re-visit the eternal “data parasite” debate. Finally, we’ll conclude with a few suggestions for summer reading. The AI Opportunity: Elevating Healthcare for All Earlier this month, I... Read More
18
May
2023
Anthony Mancini of Genmab on Growing Your Company Together with Partners
Anthony Mancini is the chief operating officer of Denmark-based Genmab, one of the leading innovators of antibody therapies for patients living with cancer and other serious diseases. After many years working as a behind-the-scenes innovator, Genmab is now becoming a significant commercial entity. In 2021, the company began marketing its first commercial product, Tidvak® (tisotumab vedotin) for the treatment of... Read More
16
May
2023
Boundless Bio Gets $100M to Fight Cancer, NewLimit Gets $40M to Defy Aging
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
May
2023
Biopharma Innovation – Beyond The Breathless Headlines
Biopharma relies on innovation to stay in business. Success depends on our collective ability to discover, develop, and deliver new products that cure or meaningfully mitigate disease over and over again. Patents allow for innovators to be rewarded, for a while. When patents expire, allowing us to purchase powerful generic medications like atorvastatin for pennies, manufacturers must come up with... Read More
11
May
2023
Thinking Big About Community Impact
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
May
2023
Creating a New Class of Medicines: John Maraganore on The Long Run
Today’s guest on The Long Run is John Maraganore. John is best known as the former CEO of Alnylam Pharmaceuticals, the RNA interference drug developer. He spent 19 years there as CEO, before stepping down at the end of 2021. Alnylam figured out how to make a new therapeutic modality — gene-silencing with double-stranded oligonucleotide therapies. Alnylam’s technology has now... Read More
4
May
2023
Lilly’s Alzheimer’s Win, Astellas Breaks Out Checkbook, & a RSV Vaccine First
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
May
2023
Preserving the Biotech Social Contract – We Should All Be Pitching In
[Editor’s Note: This is a preface by Jeremy Levin supporting the following essay by Steve Potts.] Biotech is an industrial tapestry woven together by remarkable people with deep intellect, determination, passion, and bravery all driven to create the next and best medicine. Underpinning it is an immense and complex infrastructure including capital formation, regulatory processes, patient advocacy, policy making, health... Read More
27
Apr
2023
Big Week for RNA Medicines, BMS Gets a New Boss, and a Microbiome First
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Apr
2023
Orbital Secures $270M to Make New RNA Medicines
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.